Arcturus Therapeutics Holdings Inc. ARCT is engaged in developing messenger RNA (mRNA) medicines and vaccines based on its innovative and enabling technologies. San Diego, CA-based Arcturus has ...

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with C ...

The Arcturus COVID-19 variant has arrived in the United States and is here to stay, according to experts. While it's unclear whether it will drive a summer surge, some doctors are warning that the ...

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic ...

Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...

Earnings Call Insights: Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 CEO Joseph E. Payne reported that the ARCT-032 program for Cystic Fibrosis (CF) has completed enrollment and dosing for the 5 ...

Los Angeles County Department of Public Health confirmed three cases of the Arcturus strain with "observational data" suggesting that those infected may be likely to experience pink eye Alexis Jones ...

Los Angeles County has identified its first cases of an emerging Omicron coronavirus subvariant dubbed Arcturus, a strain global health authorities are watching closely as it has been linked to an ...